LUMA Vision has secured another U.S. Food and Drug Administration clearance expanding the capabilities of its VERAFEYE cardiac procedural intelligence platform as the Dublin-based company prepares for a commercial launch in early 2027. The updated system combines intracardiac ultrasound imaging, digital anatomical reconstruction, continuous catheter tracking and procedural guidance within one platform rather than treating imaging and navigation as separate functions. LUMA says a single 360-degree imaging catheter can capture ultrasound information used to generate real-time 2D and 3D representations of the heart, valves, great vessels and surrounding structures while the system simultaneously tracks the imaging and ablation catheters.
The regulatory history is broader than one September announcement. The FDA first cleared the VERAFEYE System and Imaging Catheter in March 2025 under K242893. A newer Imaging and Guidance System received 510(k) clearance in June 2026 under K260885, followed by a Special 510(k) clearance for an updated VERAFEYE Imaging Catheter in July under K261849. The September release packages those successive changes into the commercial version LUMA intends to bring to U.S. cardiac laboratories next year.
Why does a 360-degree intracardiac imaging catheter matter during ablation?
Intracardiac echocardiography places an ultrasound catheter inside the heart so physicians can visualize cardiac structures during electrophysiology and structural procedures.
Traditional intracardiac ultrasound systems often produce sector-based images that require the operator to rotate or reposition the catheter repeatedly to keep a target or another device in view.
LUMA’s system is designed to acquire circumferential ultrasound data and reconstruct a broader anatomical representation from one catheter position. That could reduce the amount of manual repositioning required as the physician moves other tools around the chamber.
The practical importance becomes especially obvious during atrial fibrillation ablation. The physician needs to understand the atrial anatomy, track the ablation catheter and confirm where therapy has been delivered.
If the imaging catheter constantly has to be rotated to reacquire the ablation catheter, the operator’s attention is divided between maintaining the image and delivering treatment.
VERAFEYE is designed to keep both anatomy and device location visible continuously.
What does the new guidance functionality actually add?
LUMA says physicians can mark locations directly on the reconstructed anatomical model as ablation therapy is delivered.
That turns the imaging system into more than a passive ultrasound display. The platform becomes a procedural record showing where the catheter has been and where lesions are being placed.
In electrophysiology, understanding lesion location matters because durable ablation depends on creating an appropriate pattern of treatment around arrhythmogenic tissue while avoiding gaps.
Conventional electroanatomical mapping systems already provide sophisticated catheter localization, so VERAFEYE enters a field with established competitors. Its potential differentiation is combining anatomical ultrasound and navigation within the same imaging architecture.
Whether that reduces procedural time, radiation use or dependence on other mapping technologies has not yet been established in comparative clinical trials.
How do the FDA clearances differ from one another?
The March 2025 clearance covered the VERAFEYE System, Imaging Catheter and Imaging System as a Class II intravascular ultrasound device.
The June 2026 clearance covered the updated VERAFEYE Imaging and Guidance System under K260885. FDA records list the device as substantially equivalent through the traditional 510(k) pathway.
The July clearance under K261849 applies to the updated VERAFEYE Imaging Catheter and was reviewed through the Special 510(k) pathway, which is commonly used for certain modifications to a manufacturer’s own cleared device.
The distinction matters because the September press release can easily sound like VERAFEYE received its first FDA authorization. It did not. LUMA is announcing an expanded cleared configuration built on several regulatory decisions.
For PDN readers, the meaningful news is therefore capability expansion and commercial readiness rather than first U.S. market access.
What is “procedural intelligence” and how much of it is actually AI today?
LUMA uses the phrase to describe a system that combines imaging, anatomy reconstruction, device tracking and guidance instead of presenting clinicians with isolated streams of information.
The platform can analyze ultrasound data to build anatomical models and maintain catheter localization. LUMA also talks about constructing a database of real cardiac anatomy across thousands of cases, with future guidance intended to help physicians make procedural decisions rather than merely visualize anatomy.
That future ambition should not be confused with the current FDA-cleared functionality. The existing clearances cover defined imaging and guidance features, and the FDA record for K260885 states that no Predetermined Change Control Plan was authorized.
This means LUMA cannot simply add unlimited future machine-learning decision support under the assumption that the present clearance automatically covers it.
Material new capabilities may require additional regulatory review depending on intended use and risk.
Could VERAFEYE reduce fluoroscopy during heart procedures?
Potentially, because real-time intracardiac imaging and catheter tracking can provide anatomical information that otherwise might require X-ray fluoroscopy or repeated imaging.
Many electrophysiology laboratories already aim to minimize fluoroscopy using electroanatomical mapping and intracardiac echocardiography.
VERAFEYE could contribute to that trend if its continuously reconstructed anatomy and tracked catheters allow operators to navigate with less dependence on X-ray.
However, LUMA’s September announcement does not provide a randomized or comparative fluoroscopy-reduction dataset.
The platform should therefore not yet be described as proven to reduce radiation exposure.
The commercially important question is whether the integrated imaging actually changes workflow enough to produce measurable improvements in procedure time, fluoroscopy, catheter exchanges or complication rates.
Why is real-time anatomy important during atrial fibrillation ablation?
Cardiac anatomy is not static. The heart beats, patients breathe and structures move relative to one another.
A pre-procedure CT or MRI provides valuable anatomy, but it represents the heart at a different moment under different physiological conditions.
Intracardiac ultrasound can show anatomy as the procedure happens.
Atrial fibrillation ablation often focuses on tissue around the pulmonary veins. Physicians need to understand the relationship between those veins, the left atrium, the septum and nearby structures while safely manipulating catheters.
Real-time imaging can also help identify pericardial effusion, guide transseptal puncture and monitor other procedural steps.
VERAFEYE’s promise is that the anatomical image can simultaneously become a navigational model rather than remaining a separate ultrasound view.
How does LUMA compete with established cardiac mapping companies?
Electrophysiology is dominated by large medtech companies with deeply installed mapping systems, ablation catheters and physician training ecosystems.
Breaking into that environment is difficult because hospitals do not change platforms based solely on a visually attractive interface.
A new system needs either to improve clinical outcomes, simplify procedures, reduce capital or disposable costs, or provide capabilities unavailable from existing platforms.
LUMA’s potential advantage is its imaging-first architecture. Instead of creating a largely geometry-based electroanatomical map and adding ultrasound as a supporting modality, VERAFEYE derives anatomy directly from 360-degree ultrasound and overlays device tracking.
That could be particularly valuable if physicians trust the resulting anatomy as a faithful representation of what is actually inside the heart at that moment.
The company will need strong clinical and workflow data to turn that conceptual advantage into commercial adoption.
Why does the early 2027 launch timeline matter?
The sequential clearances suggest LUMA has moved beyond proof-of-concept engineering and into commercialization preparation.
The company now has cleared hardware and system functionality but still needs manufacturing scale, physician training, hospital contracts and integration into existing electrophysiology workflows.
Cardiac laboratories are complex environments containing equipment from multiple vendors. A new imaging platform must interface smoothly with ablation systems, recording equipment and other devices already in the room.
Service support also matters. Hospitals expect critical procedural equipment to have rapid maintenance and replacement infrastructure.
The early 2027 launch therefore represents a different challenge from regulatory clearance. FDA authorization establishes that LUMA can market the defined system. Commercial success depends on convincing laboratories to make room for it.
What evidence will determine whether VERAFEYE becomes a major platform?
Procedure efficiency should be one of the first metrics. LUMA can test whether physicians spend less time repositioning imaging catheters, whether overall procedure duration falls and whether the system reduces use of additional mapping tools.
Safety is another key question. Better visualization could theoretically reduce complications during transseptal access or catheter manipulation, but those benefits need clinical evidence.
Image quality must also remain consistent across patient anatomies. Obesity, chamber size, rhythm and catheter position can all affect intracardiac ultrasound.
Finally, physicians will judge whether the platform genuinely simplifies decision-making or simply creates another screen of information to interpret.
The September clearance gives LUMA the regulatory foundation to begin answering those commercial questions at scale. VERAFEYE’s pitch is compelling because it addresses a common procedural frustration: imaging, mapping and treatment often occupy separate technological silos. The platform’s success will depend on proving that combining them produces more than a cleaner user interface.
